Tag: MONOGRAPH

  • Topilitumide

    Topical nonsteroidal antiandrogen of the perfluoroacylamido-arylpropanamide class with rapid serum hydrolysis and local androgen receptor suppression

    A rationally designed, serum-labile topical antiandrogen engineered from the flutamide scaffold for androgen receptor suppression in dermal tissue without systemic absorption, developed by Biophysica Inc. and marketed as Eucapil for androgenetic alopecia in Central European jurisdictions.

    Abstract

    Topilutamide (International Nonproprietary Name; also known as fluridil and by the development code BP-766) is a nonsteroidal antiandrogen of the perfluoroacylamido-arylpropanamide structural class, rationally designed for topical application in the treatment of androgenetic alopecia. The compound represents a deliberate medicinal chemistry solution to the principal limitation of systemic nonsteroidal antiandrogens such as flutamide, bicalutamide, and enzalutamide: hepatotoxicity and sexual adverse effects arising from systemic androgen receptor blockade. The design strategy incorporated perfluoroalkyl moieties into the flutamide analog BP-34 to produce a molecule that retains high-affinity androgen receptor antagonism and androgen receptor protein downregulation in dermal tissue while undergoing rapid hydrolytic decomposition upon contact with human serum (half-life approximately 6 hours at 37 degrees Celsius; undetectable after 48 hours), yielding the inactive fragments BP-34 and trifluoroacetic acid. Neither parent compound nor metabolites have been detected in human serum following chronic topical application at the marketed 2 percent concentration, establishing a pharmacokinetic profile that functionally eliminates systemic antiandrogenic exposure.

    In vitro pharmacology in LNCaP human prostate cancer cells demonstrates concentration-dependent suppression of androgen receptor protein expression: approximately 40 percent reduction at 3 micromolar and up to 95 percent reduction at 10 micromolar following 48-hour incubation [1, 2]. Comparative binding studies suggest that topilutamide binds the androgen receptor with approximately 9- to 15-fold greater affinity than bicalutamide and hydroxyflutamide, though these findings require further validation with rigorous competitive binding assays [2]. The mechanism appears to involve both direct receptor antagonism and receptor protein downregulation, distinguishing topilutamide from pure competitive antagonists that stabilize the receptor in an inactive conformation.

    The clinical evidence base is limited to two published trials comprising 53 total participants. The pivotal randomized, double-blind, placebo-controlled trial in 43 men with androgenetic alopecia demonstrated significant promotion of anagen-phase hair growth: anagen percentage increased from 75.7 percent to 85.1 percent at 3 months and 87 percent at 9 months with daily topical application of 2 percent fluridil in isopropanol vehicle [3]. Sexual function, libido, hematology, and blood chemistry values remained within normal limits throughout the study period, and no systemic absorption of the parent compound or its metabolites was detectable. A second open-label study in 11 women with female pattern hair loss demonstrated significant increases in hair shaft diameter at 6 and 9 months but did not achieve statistical significance on anagen-telogen ratio endpoints [4]. The compound was introduced for cosmetic use in 2003 and is marketed exclusively in the Czech Republic and Slovakia by Interpharma Praha (a subsidiary of Otsuka Pharmaceutical) under the brand name Eucapil. It is not approved by the United States Food and Drug Administration, the European Medicines Agency, or any other major regulatory authority for pharmaceutical use. The patent expired in 2020. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Cortexin

    Polypeptide bioregulator complex derived from cerebral cortex with neurotrophic, neuroprotective, and nootropic activity

    A heterogeneous low-molecular-weight neuropeptide preparation extracted from the cerebral cortex of young cattle and pigs, registered in the Russian Federation as a neuroprotective agent for cerebrovascular disorders, traumatic brain injury, cognitive impairment, and perinatal central nervous system lesions, distinguished from Cerebrolysin by cortex-specific sourcing and intramuscular administration.

    Abstract

    Cortexin is a lyophilized complex of water-soluble polypeptide fractions with molecular weights ranging from 1,000 to 10,000 Daltons, obtained by acetic acid extraction from the cerebral cortex of cattle and pigs younger than 12 months of age. The preparation contains predominantly acidic and neutral polypeptides (70 to 95 percent of total mass), free amino acids (including glutamic acid, aspartic acid, glycine, serine, lysine, and alanine as quantitatively predominant species), and trace quantities of vitamins, minerals, and fatty acids. Unlike single-sequence peptide therapeutics, Cortexin is a heterogeneous mixture without a defined primary structure, and its pharmacological activity is attributed to the collective action of multiple bioactive peptide fractions rather than to any single molecular entity.

    The compound was developed within the Soviet and subsequently Russian bioregulator research program led by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology beginning in the 1980s, with the first clinical applications in military and aerospace medicine. The compound is registered in Russia, Ukraine, Kazakhstan, Belarus, Uzbekistan, and several other Commonwealth of Independent States jurisdictions for the treatment of acute and chronic cerebrovascular disorders, traumatic brain injury, cognitive impairment, encephalopathy of various origins, epilepsy as adjunctive therapy, and perinatal central nervous system lesions in children. It is not registered or approved in the European Union, the United States, Japan, or any jurisdiction with International Council for Harmonisation regulatory standards.

    The molecular mechanisms of Cortexin are pleiotropic and incompletely characterized at the individual peptide level. Demonstrated activities include modulation of glutamatergic transmission through interaction with AMPA receptors, kainate receptors, and metabotropic glutamate receptors (mGluR1 and mGluR5); GABAergic modulation through GABA-A receptor binding; activation of neurotrophic signaling cascades including brain-derived neurotrophic factor and nerve growth factor pathways; antioxidant activity through restoration of pro-oxidant and antioxidant system balance; anti-inflammatory action at both cerebral and systemic levels; and anti-apoptotic effects on neurons under ischemic and excitotoxic stress. Radioactively labeled Cortexin peptides have been demonstrated to cross the blood-brain barrier in mice, supporting direct central nervous system activity. Neuron-specific proteins including beta-5-tubulin, creatine kinase B, and protein 14-3-3 alpha/beta have been identified as molecular partners of Cortexin peptides in brain tissue.

    The clinical evidence base for Cortexin is substantial within the Russian-language medical literature but limited in the international peer-reviewed literature. A multicenter study of cognitive dysfunction in children demonstrated improvement in attention, visual memory, and thinking in pediatric patients with consequences of perinatal central nervous system lesions. In cerebral palsy with comorbid epilepsy, Cortexin as adjunctive therapy reduced seizure frequency by more than two-fold in 36.9 percent of patients while improving motor function. Comparative preclinical studies have demonstrated neuroprotective efficacy comparable to Cerebrolysin and superior to Actovegin in rat models of acute and chronic brain ischemia. A systematic review of animal-derived nootropics noted that the limited number of eligible Cortexin studies precluded meta-analysis, though available data suggested potential efficacy with no safety concerns. The compound is generally well tolerated; the principal adverse events are injection site reactions (8 to 15 percent), headache (5 to 12 percent), dizziness (3 to 8 percent), and rare hypersensitivity reactions including anaphylaxis. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Capromorelin

    Orally active pyrazolinone-piperidine dipeptide growth hormone secretagogue receptor type 1a (GHS-R1a) agonist

    A non-peptide ghrelin receptor agonist developed at Pfizer as a peptidomimetic growth hormone secretagogue for age-related functional decline, subsequently approved in veterinary medicine for appetite stimulation in dogs and weight management in cats with chronic kidney disease.

    Abstract

    Capromorelin (CP-424,391) is an orally active, non-peptide agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a, the ghrelin receptor) belonging to the pyrazolinone-piperidine dipeptide structural class. The compound was discovered at Pfizer Global Research and Development through systematic structure-activity optimization of peptidomimetic scaffolds and was selected as a clinical development candidate on the basis of high receptor affinity (Ki = 7 nM at human GHS-R1a), potent functional activity (EC50 = 3 nM in rat pituicyte growth hormone release assay), oral bioavailability, and robust in vivo growth hormone secretion in rodent and canine models [1, 2]. Capromorelin mimics the endogenous acylated peptide hormone ghrelin by binding the GHS-R1a receptor on somatotroph cells of the anterior pituitary gland and on hypothalamic neurons, activating Gq/11-coupled phospholipase C signaling, intracellular calcium mobilization, and consequent pulsatile growth hormone release through a pathway mechanistically distinct from and synergistic with the growth hormone releasing hormone (GHRH) receptor pathway. Secondary pharmacological activities include appetite stimulation through hypothalamic orexigenic circuits, transient elevation of circulating cortisol and prolactin, and sustained elevation of insulin-like growth factor 1 (IGF-1) on chronic dosing. Human clinical development was subsequently discontinued; the compound did not advance to Phase III registration trials for age-related sarcopenia or functional decline. These veterinary approvals represent the only registered therapeutic applications of capromorelin as of the most recent monograph revision. The compound is the first and only FDA-approved ghrelin receptor agonist for appetite stimulation in companion animals and demonstrates the translational validity of the GHS-R1a mechanism for orexigenic and anabolic applications. Pharmacokinetics in dogs are characterized by rapid oral absorption (Tmax approximately 0.83 hours), moderate oral bioavailability (44 percent), hepatic metabolism predominantly through CYP3A4 and CYP3A5 mediated N-dealkylation and O-debenzylation, and a short terminal elimination half-life (approximately 1.2 hours in dogs, 2.4 hours in rats) [2, 15, 16]. The compound is well tolerated at studied doses; the principal adverse events across species are transient hypersalivation, mild emesis, loose stools, and transient increases in serum cortisol and glucose concentrations that normalize within hours of dosing. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Livagen

    Synthetic tetrapeptide bioregulator with hepatoprotective, epigenetic chromatin-remodeling, and enkephalinase-inhibitory activity

    A Khavinson-class synthetic tetrapeptide (Lys-Glu-Asp-Ala) developed at the St. Petersburg Institute of Bioregulation and Gerontology as a liver-targeted bioregulator, distinguished by its capacity to induce chromatin decondensation in aged cells, inhibit enkephalin-degrading enzymes in human serum, and restore hepatocyte protein synthesis in senescent tissue.

    Abstract

    Livagen (Lys-Glu-Asp-Ala; single-letter code KEDA) is a synthetic tetrapeptide bioregulator developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology as a liver-targeted member of the broader Khavinson short-peptide bioregulator family. The compound is characterized by three principal pharmacological activities studied across cell culture, animal, and limited human research: (1) epigenetic chromatin remodeling through induction of deheterochromatinization of pericentromeric structural heterochromatin and facultative heterochromatin in lymphocytes and hepatocytes from aged organisms, with consequent reactivation of ribosomal genes and euchromatic loci silenced during aging; (2) potent inhibition of enkephalin-degrading serum peptidases (IC50 approximately 20 micromolar), exceeding the inhibitory potency of established peptidase inhibitors including puromycin, leupeptin, and D-phenylalanyl-alanyl-arginine-p-nitroanilide, without direct interaction with mu or delta opioid receptors; and (3) restoration of protein synthesis rhythms and metabolic function in hepatocyte cultures from aged rats to levels characteristic of young animals at nanomolar concentrations.

    The chromatin-remodeling mechanism has been demonstrated in cultured lymphocytes from human subjects aged 75 to 88 years, in which Livagen induced activation of ribosomal genes, decondensation of pericentromeric heterochromatin of chromosomes 1, 9, and 16, and release of genes repressed through age-related condensation of euchromatic regions. This deheterochromatinization effect is shared with other Khavinson bioregulator peptides (Vilon, Epitalon, Cortagen) but appears tissue-preferential for hepatic and lymphoid lineages at the concentrations studied. Molecular modeling studies of the broader Khavinson peptide class suggest that short peptides interact with the nucleosome, histone proteins, and double-stranded DNA through steric and electrostatic complementarity, altering histone modification patterns and the accessibility of regulatory regions to transcription factors.

    In experimental models of liver pathology (acute and chronic hepatitis, liver fibrosis), the KEDA tetrapeptide demonstrated hepatoprotective and immunoprotective effects including normalization of total bilirubin, cholesterol, alanine aminotransferase, and aspartate aminotransferase levels; stimulation of tissue repair; and decreased destructive dystrophic processes in liver stroma. The maximal hepatoprotective effect was observed in aged animals, consistent with the bioregulator hypothesis that these peptides primarily restore age-depleted signaling. In aged rat hepatocyte cultures, Livagen restored circahoralian rhythms of protein synthesis to patterns characteristic of young specimens at nanomolar concentrations. A separate line of investigation demonstrated that oral administration of Livagen for two weeks modulated digestive enzyme activity in rats in an age-dependent manner, reducing enzyme activity in young animals while increasing it in old animals toward levels observed in young controls.

    The compound is resistant to hydrolysis by small intestinal peptidases and is not degraded to a measurable extent by the peptide hydrolases of the small intestine. Formal pharmacokinetic characterization meeting Western regulatory standards has not been published. The compound is not approved by any major Western regulatory authority (FDA, EMA) and is not registered on ClinicalTrials.gov. The primary research literature originates from Russian and Georgian institutions, and independent Western replication of key findings remains limited. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Tuftsin

    Endogenous immunostimulatory tetrapeptide derived from the CH2 domain of immunoglobulin G

    A spleen-dependent, IgG-derived tetrapeptide that activates phagocytic cells through neuropilin-1 receptor binding, stimulating macrophage phagocytosis, chemotaxis, and tumoricidal activity, and serving as the structural parent of the anxiolytic heptapeptide Selank.

    Abstract

    Tuftsin (L-threonyl-L-lysyl-L-prolyl-L-arginine) is an endogenous tetrapeptide corresponding to residues 289 through 292 of the CH2 domain of the immunoglobulin G (IgG) heavy chain. First identified in 1970 by Victor A. Najjar and Keisuke Nishioka at the Tufts University School of Medicine during investigations of phagocytosis by polymorphonuclear granulocytes, the peptide derives its name from its institutional origin and has since become the prototype endogenous immunostimulatory peptide. Tuftsin is not synthesized de novo but is liberated from a larger IgG-associated polypeptide termed leukokinin through the sequential action of two proteases: tuftsin-endocarboxypeptidase, a splenic enzyme that cleaves the C-terminal bond of the tetrapeptide within the intact immunoglobulin, and leukokinase, a serine protease on the outer membrane of phagocytic cells that releases the active N-terminal tetrapeptide from the partially processed fragment. This two-step enzymatic liberation places the spleen as an obligate organ in tuftsin physiology and accounts for the well-documented tuftsin deficiency, impaired phagocytic function, and increased susceptibility to overwhelming bacterial infection observed following splenectomy.

    The molecular pharmacology of tuftsin centers on its binding to neuropilin-1 (NRP1), a single-pass transmembrane glycoprotein that also serves as a co-receptor for vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta). Tuftsin binds the b1 domain of neuropilin-1 through a motif similar to the C-terminal sequence encoded by exon 8 of VEGF165, and signals through TGF-beta receptor 1 (a co-receptor of NRP1) via the canonical Smad3 phosphorylation pathway, with concurrent reduction in Akt phosphorylation. At the cellular level, tuftsin binding stimulates phagocytosis, pinocytosis, chemotaxis, respiratory burst (superoxide anion and hydrogen peroxide generation), antigen presentation, and tumoricidal activity in monocytes, macrophages, neutrophils, microglia, and Kupffer cells. Intracellular calcium serves as a critical second messenger in tuftsin-mediated phagocyte activation. In neuroinflammatory models, tuftsin promotes an anti-inflammatory M2 microglial phenotype shift, suppresses pro-inflammatory Th1 responses, upregulates Th2 responses, and expands regulatory T cell populations.

    Pharmacokinetically, tuftsin is an extremely labile peptide in vivo, with a plasma half-life of approximately 16 minutes owing to rapid degradation by serum aminopeptidases and carboxypeptidases. Oral bioavailability is negligible because of gastric peptidase destruction. The rapid enzymatic clearance has been the principal barrier to clinical development.

    The most significant translational legacy of tuftsin is the development of Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro), a synthetic heptapeptide analog in which the tuftsin sequence is extended at the C-terminus with a Pro-Gly-Pro tripeptide motif that confers resistance to enzymatic degradation and facilitates blood-brain barrier penetration. Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and is approved in Russia as a nasal spray for generalized anxiety disorder and neurasthenia. Selank exhibits pronounced anxiolytic, nootropic, and immunomodulatory activity through mechanisms including allosteric modulation of GABA-A receptors and modulation of monoamine neurotransmitter metabolism, and does so without the sedation, tolerance, or dependence associated with benzodiazepines.

    Beyond Selank, tuftsin has been developed as a targeting ligand for liposomal and nanoparticle drug delivery systems. Palmitoyl tuftsin grafted onto liposome surfaces enables selective binding to phagocytic cells and has demonstrated augmented antitumor efficacy of encapsulated cytotoxic agents (etoposide, doxorubicin, curcumin) against fibrosarcoma and Ehrlich ascites carcinoma in murine models. Tuftsin-bearing liposomes have also been used to deliver antimicrobial agents to macrophage-resident intracellular pathogens including Leishmania and Plasmodium species.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Thymalin

    Thymic polypeptide bioregulator complex with immunomodulatory and geroprotective activity

    A heterogeneous polypeptide complex isolated from calf thymus, developed at the Military Medical Academy in Leningrad as a thymic bioregulator for immune restoration, distinguished from other thymic peptide preparations by its multicomponent composition containing the immunomodulatory dipeptides L-glutamyl-L-tryptophan and L-lysyl-L-glutamic acid and the tripeptide L-glutamyl-L-aspartyl-L-proline.

    Abstract

    Thymalin is a standardized polypeptide complex isolated from the thymus gland of calves by acid hydrolysis and ultrafiltration, containing peptide fractions in the 1,000 to 10,000 dalton molecular weight range. Developed at the Military Medical Academy in Leningrad (now Saint Petersburg) by Vladimir Khavinson and Vyacheslav Morozov in the 1970s, the preparation was registered as an immunomodulatory pharmaceutical in the Soviet Union in 1982 and has remained in clinical use in the Russian Federation for more than four decades. Unlike the structurally defined thymic peptides thymosin alpha-1 (a 28-amino-acid single-sequence peptide), thymulin (a zinc-dependent nonapeptide), and thymopentin (a synthetic pentapeptide fragment of thymopoietin), Thymalin is a multicomponent extract whose principal bioactive constituents have been identified by reversed-phase high-performance liquid chromatography as the dipeptide L-glutamyl-L-tryptophan (Glu-Trp, subsequently developed independently as Thymogen), the dipeptide L-lysyl-L-glutamic acid (Lys-Glu, developed as Vilon), and the tripeptide L-glutamyl-L-aspartyl-L-proline (Glu-Asp-Pro, developed as Crystagen). The molecular mechanism of the immunoprotective activity is attributed to the capacity of these short peptides to bind selectively to double-stranded DNA sequences and to histone proteins, thereby modulating chromatin conformation, gene expression, and the synthesis of immune system proteins including interleukins, interferons, heat-shock proteins, and components of the fibrinolytic system. In experimental systems, Thymalin stimulates the differentiation and functional activity of T-lymphocyte subpopulations (CD4+ and CD8+), normalizes the ratio of T-helper to T-suppressor cells, enhances natural killer cell activity and phagocytosis, and modulates the balance between pro-inflammatory and anti-inflammatory cytokines. The geroprotective properties of Thymalin are supported by a prospective clinical observation of 266 elderly subjects over 6 to 8 years conducted at the St. Petersburg Institute of Bioregulation and Gerontology and the Institute of Gerontology of the Ukrainian Academy of Medical Sciences, in which Thymalin-treated subjects exhibited 2.0- to 2.1-fold lower mortality compared to controls receiving standard geriatric care, with further reductions (4.1-fold lower mortality) observed in a subgroup receiving annual combined Thymalin and Epithalamin treatment for 6 years. In vitro studies have demonstrated that Thymalin reduces expression of the stem cell markers CD44 and CD117 by 2- to 3-fold while increasing expression of CD28 (a marker of mature T lymphocytes) by 6.8-fold, consistent with stimulation of hematopoietic stem cell differentiation into functional T cells. The safety record across more than 40 years of clinical use indicates minimal adverse events, principally limited to injection-site reactions. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Carnosic-Acid

    Phenolic abietane diterpene with pro-electrophilic Nrf2/Keap1 pathway activation and pleiotropic antioxidant, anti-inflammatory, and neuroprotective activity

    A catechol-type abietane diterpene isolated from Rosmarinus officinalis and Salvia officinalis, distinguished by a pro-electrophilic mechanism of Nrf2 activation through oxidative conversion to a quinone intermediate that S-alkylates Keap1 cysteine residues, conferring context-dependent neuroprotective, anti-inflammatory, and cytoprotective activity selectively in tissues under oxidative stress.

    Abstract

    Carnosic acid is the principal lipophilic phenolic diterpene of rosemary (Salvia rosmarinus, formerly Rosmarinus officinalis) and common sage (Salvia officinalis), constituting approximately 1.5 to 5 percent of dried leaf mass and serving as the primary bioactive antioxidant constituent of commercial rosemary extracts designated E392 in European food-additive regulations. The compound belongs to the abietane diterpenoid structural class and is characterized by a catechol (ortho-dihydroxybenzene) moiety on ring C of the phenanthrene skeleton that confers both direct radical-scavenging activity and, more distinctively, pro-electrophilic activation of the Keap1/Nrf2/ARE cytoprotective transcriptional pathway. Under conditions of oxidative stress, the catechol ring of carnosic acid undergoes two-electron oxidation to an ortho-quinone electrophile that forms covalent thioether adducts with reactive cysteine residues (principally Cys151, Cys273, and Cys288) on the Keap1 sensor protein, releasing the transcription factor Nrf2 from proteasomal degradation and permitting its nuclear translocation and transactivation of antioxidant response element (ARE)-driven phase 2 genes including heme oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase 1 (NQO1), glutamate-cysteine ligase catalytic subunit (GCLC), and thioredoxin reductase 1. This pro-electrophilic mechanism is pharmacologically significant because it renders the compound conditionally active: carnosic acid is converted to its electrophilic effector form preferentially in tissues experiencing elevated reactive oxygen species flux, thereby concentrating cytoprotective gene induction at sites of pathological oxidative damage rather than systemically. The neuroprotective activity of carnosic acid has been characterized in multiple rodent models of neurodegeneration and neuroinflammation, including 6-hydroxydopamine and MPTP models of Parkinson’s disease, middle cerebral artery occlusion models of ischemic stroke, controlled cortical impact models of traumatic brain injury, and transgenic mouse models of Alzheimer’s disease (5xFAD). In the 5xFAD model, a diacetyl pro-drug derivative (diAcCA) with improved oral stability and approximately 20 percent greater bioavailability than the parent compound reduced amyloid plaque burden, suppressed microglial and astrocytic inflammatory gene expression, and normalized spatial and working memory at oral doses translating to feasible human-equivalent exposures. Beyond neuroprotection, carnosic acid has demonstrated preclinical anti-inflammatory activity through suppression of NF-kappaB signaling and reduction of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) in models of colitis, hepatotoxicity, periodontitis, and high-fat-diet-induced neuroinflammation; antiproliferative and pro-apoptotic activity against multiple cancer cell lines (melanoma, glioma, breast, prostate, colon, renal, esophageal) through modulation of PI3K/AKT/mTOR, MAPK, and STAT3 signaling pathways; hepatoprotective activity against acetaminophen-induced and carbon-tetrachloride-induced liver injury; and antiadipogenic activity through PPARgamma modulation. Pharmacokinetically, carnosic acid is orally bioavailable (approximately 40 to 65 percent in rodent models), undergoes extensive hepatic phase II glucuronidation, and achieves measurable plasma concentrations in humans after oral administration of standardized rosemary extract. Human clinical data remain limited; no registration trials have been completed for any therapeutic indication, and the compound is not approved as a medicine by any regulatory authority. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Mirodenafil

    Selective phosphodiesterase type 5 (PDE5) inhibitor of the pyrrolopyrimidinone structural class

    A second-generation pyrrolopyrimidinone PDE5 inhibitor developed by SK Chemicals in South Korea for erectile dysfunction, distinguished from first-generation agents by approximately 10-fold higher PDE5 affinity, superior isoenzyme selectivity, and an emerging multimodal research profile in Alzheimer’s disease through cGMP/PKG/CREB signaling, autophagy enhancement, and neuroinflammatory modulation.

    Abstract

    Mirodenafil (SK3530) is a potent, selective, and reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) belonging to the pyrrolopyrimidinone structural class. The compound inhibits PDE5 with an IC50 of 0.34 nmol/L, approximately 10-fold more potent than sildenafil (IC50 3.5 nmol/L), and exhibits selectivity ratios of approximately 48,235-fold over PDE1, 254,000-fold over PDE3, and greater than 10,000-fold over PDE11. Pharmacokinetically, mirodenafil is rapidly absorbed after oral administration with a time to maximum plasma concentration of 0.67 to 1.5 hours, an elimination half-life of 1.32 to 3.0 hours, oral bioavailability of 24 to 43 percent for the parent compound, and approximately 97 percent plasma protein binding. Metabolism is predominantly hepatic through CYP3A4-mediated N-dealkylation to the active metabolite SK-3541, which retains approximately one-tenth of the PDE5 inhibitory activity of the parent compound. Clinical efficacy in erectile dysfunction has been demonstrated in multiple randomized, double-blind, placebo-controlled trials totaling more than 700 patients across general, diabetic, and hypertensive populations, with improvements in the International Index of Erectile Function erectile function domain score of 7 to 12 points over placebo. Adverse events are predominantly mild to moderate, with flushing (3.3 to 24.1 percent) and headache (1.8 to 14.8 percent) as the most common; no visual disturbances or myalgia have been reported in published trials. Beyond erectile dysfunction, mirodenafil (designated AR1001 by licensee AriBio) has entered clinical development for Alzheimer’s disease on the basis of preclinical evidence demonstrating multimodal neuroprotective activity: activation of the cGMP/PKG/CREB signaling pathway, enhancement of autophagy-lysosome clearance of amyloid-beta and phosphorylated tau, suppression of neuroinflammation, and improvement of mitochondrial function. The global Phase 3 POLARIS-AD trial, enrolling approximately 1,150 participants with early Alzheimer’s disease across 200 sites under FDA, EMA, and MHRA authorization, is currently underway with a primary endpoint of change in Clinical Dementia Rating Sum of Boxes at 52 weeks. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Urolithin-B

    Dibenzopyranone gut microbiota metabolite derived from ellagitannin catabolism with anabolic, anti-inflammatory, antioxidant, and neuroprotective activity

    A monohydroxylated dibenzo[b,d]pyran-6-one produced by colonic microflora from dietary ellagitannins and ellagic acid, distinguished from the structurally related urolithin A by selective promotion of skeletal muscle protein synthesis via androgen receptor and mTORC1 signaling, and by protective activity against islet amyloid polypeptide proteotoxicity.

    Abstract

    Urolithin B (3-hydroxy-6H-dibenzo[b,d]pyran-6-one; CAS 1139-83-9) is one of the two principal terminal metabolites generated by human colonic microflora from dietary ellagitannins and ellagic acid, polyphenolic compounds abundant in pomegranates, walnuts, raspberries, strawberries, and certain tree nuts. Unlike its dihydroxylated isomer urolithin A (3,8-dihydroxyurolithin), which has advanced into human clinical trials primarily on the basis of mitophagy induction and mitochondrial quality control, urolithin B is distinguished by a pharmacological profile centered on skeletal muscle anabolism, neuroprotection through PI3K/Akt survival signaling, anti-inflammatory activity through NF-kappaB and NLRP3 inflammasome suppression, and a unique capacity to attenuate islet amyloid polypeptide (IAPP) proteotoxicity relevant to type 2 diabetes pathogenesis. The skeletal muscle activity, formally characterized by Rodriguez et al. (2017), demonstrated that urolithin B at 15 micromolar enhanced C2C12 myotube protein synthesis by 96.1 percent, increased myotube diameter and fusion index, suppressed the ubiquitin-proteasome degradation pathway, and operated through an androgen receptor to mTORC1 signaling axis independent of Akt phosphorylation. Anticancer activity has been demonstrated in hepatocellular carcinoma (through Wnt/beta-catenin inactivation), osteosarcoma (G2/M arrest and MMP-2/-9 targeting), bladder cancer, leukemia, triple-negative breast cancer, and esophageal cancer cell lines. Bone-protective activity was reported in ovariectomy-induced osteoporosis models through inhibition of osteoclast formation via ERK/NF-kappaB suppression. The compound is produced endogenously only by individuals with the urolithin metabotype B (UM-B) gut microbiota profile, estimated at approximately 10 to 50 percent of the population depending on ethnicity and dietary pattern. Urolithin B undergoes extensive hepatic phase II conjugation to glucuronide and sulfate metabolites; circulating total urolithin concentrations in UM-B individuals following ellagitannin consumption range from 0.003 to 5.2 micromolar, with urinary excretion reaching up to 50 micromolar. No human clinical trials of exogenous urolithin B supplementation have been completed as of monograph preparation. The compound is available as a research-grade preparation from multiple chemical suppliers at greater than 95 percent purity. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Sulforaphane

    Isothiocyanate organosulfur compound and potent Nrf2 pathway activator derived from glucoraphanin in cruciferous vegetables

    A dietary isothiocyanate first isolated from broccoli at Johns Hopkins University as the most potent naturally occurring inducer of mammalian phase 2 cytoprotective enzymes, now established as a multimechanistic agent acting through Keap1-Nrf2 electrophilic signaling, NF-kappaB suppression, and histone deacetylase inhibition across chemopreventive, metabolic, neurobehavioral, and anti-inflammatory research applications.

    Abstract

    Sulforaphane (1-isothiocyanato-4-methylsulfinylbutane) is a low-molecular-weight isothiocyanate generated by myrosinase-catalyzed hydrolysis of the glucosinolate glucoraphanin, found at highest concentration in broccoli sprouts and at progressively lower concentration in mature broccoli, Brussels sprouts, cauliflower, and other cruciferous vegetables. First identified in 1992 by Paul Talalay and colleagues at the Johns Hopkins University School of Medicine as the most potent naturally occurring inducer of mammalian phase 2 detoxification enzymes, sulforaphane has become the most extensively studied dietary isothiocyanate in human pharmacology and the reference compound for nutrigenomic Nrf2 activation. The primary molecular mechanism is electrophilic modification of reactive cysteine residues on the Kelch-like ECH-associated protein 1 (Keap1) sensor, leading to stabilization and nuclear translocation of the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) and subsequent transcriptional upregulation of a battery of cytoprotective genes including NAD(P)H:quinone oxidoreductase 1 (NQO1), heme oxygenase-1 (HO-1), glutathione S-transferases (GSTs), and thioredoxin reductase. Sulforaphane activates Nrf2 with a potency approximately 13-fold greater than curcumin, 18-fold greater than silymarin, and over 100-fold greater than resveratrol in standardized NQO1 inducer assays. A second established mechanism is the suppression of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) signaling through inhibition of IkappaB-alpha phosphorylation and degradation, producing broad anti-inflammatory activity. A third mechanism, characterized by Myzak et al. in 2004, is inhibition of histone deacetylase (HDAC) enzymes by the mercapturic acid pathway metabolites sulforaphane-cysteine and sulforaphane-N-acetylcysteine, producing epigenetic reactivation of tumor suppressor genes including p21 and Bax. Pharmacokinetics in humans are characterized by rapid oral absorption (peak plasma concentration within 1 to 3 hours), a short elimination half-life of approximately 1.8 to 2.2 hours, extensive metabolism through the mercapturic acid (glutathione conjugation) pathway, and urinary excretion of 60 to 80 percent of administered sulforaphane equivalents within 24 hours. Oral bioavailability of free sulforaphane is approximately 70 to 80 percent, while bioavailability from the glucoraphanin precursor is approximately 10 to 40 percent depending on myrosinase activity and interindividual variation in gut microbial glucosinolate hydrolysis. Over 80 interventional clinical trials have examined sulforaphane or sulforaphane-yielding preparations in human subjects across indications including cancer chemoprevention (prostate, breast, lung, colorectal, bladder), autism spectrum disorder, type 2 diabetes, schizophrenia, chronic obstructive pulmonary disease, Helicobacter pylori infection, and air pollution detoxification. The Singh et al. (2014) randomized placebo-controlled trial in young men with moderate to severe autism spectrum disorder demonstrated substantial and reversible behavioral improvement on the Aberrant Behavior Checklist and Social Responsiveness Scale after 18 weeks of daily sulforaphane administration. The Axelsson et al. (2017) trial in obese patients with dysregulated type 2 diabetes demonstrated reduced fasting blood glucose and improved glycated hemoglobin with concentrated broccoli sprout extract. The compound is generally well tolerated; the principal adverse events are mild gastrointestinal disturbance (flatulence, bloating, loose stools). Goitrogenic potential at high doses is a theoretical concern for individuals with pre-existing thyroid dysfunction. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.